Literature DB >> 10982757

Hodgkin's disease risk is increased in patients with ulcerative colitis.

D Palli1, G Trallori, S Bagnoli, C Saieva, O Tarantino, M Ceroti, G d'Albasio, F Pacini, A Amorosi, G Masala.   

Abstract

BACKGROUND & AIMS: All patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) residing in Florence, Italy, in 1978-1992 were identified and included in a population-based study of cancer risk evaluation.
METHODS: A total of 920 patients were followed up (median, 11 years), and 64 newly diagnosed malignancies were identified by linkage to the local cancer registry. Expected cases were calculated on the basis of age- and sex-specific cancer incidence rates to estimate relative risks in comparison with the general population.
RESULTS: Overall, cancer incidence rates were not increased. A significant excess risk of Hodgkin's disease was observed among patients with UC (standardized incidence ratio, 9.3; 95% confidence interval [CI], 2.5-23.8). Respiratory tract cancers were significantly reduced to one fourth of the expected rate in patients with UC, but tended to be increased among patients with CD, who had a 50% higher risk of cancer at all sites. Only a nonsignificant, modestly increased risk of colorectal cancer was observed.
CONCLUSIONS: A strongly increased risk of Hodgkin's disease was evident in this first cancer follow-up of a representative series of patients with UC in a Mediterranean country. Two divergent risk patterns of respiratory tract cancers, possibly explained by differences in smoking habits, emerged in the 2 inflammatory bowel diseases.

Entities:  

Mesh:

Year:  2000        PMID: 10982757     DOI: 10.1053/gast.2000.16487

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

1.  Colorectal cancers in ulcerative colitis from a low-prevalence area for colon cancer.

Authors:  Devendra Desai; Sudeep Shah; Abhijit Deshmukh; Philip Abraham; Anand Joshi; Tarun Gupta; Ramesh Deshpande; Varun Khandagale; Siji George
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Large cell lymphoma presenting as a flare of colitis in a patient with common variable immune deficiency.

Authors:  Megan Dunnigan; Harris Yfantis; Aaron P Rapoport; Keya Hosseinzadeh; Christopher D Gocke; Raymond K Cross
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.199

3.  Risk of lymphoma: inflammatory bowel disease and immunomodulators.

Authors:  Y S Ang; R J Farrell
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

Review 4.  Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Authors:  Peter-Laszlo Lakatos; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

5.  A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease.

Authors:  J Claire Wilson; Raoul I Furlano; Susan S Jick; Christoph R Meier
Journal:  J Gastroenterol       Date:  2016-04-07       Impact factor: 7.527

Review 6.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

7.  Peripheral T-cell lymphoma in a patient with Crohn's disease.

Authors:  Srilakshmi Sudha Kollepara; Mohammad Muhsin Chisti; Seerin Viviane Shatavi; Ishmael A Jaiyesimi
Journal:  BMJ Case Rep       Date:  2013-10-10

8.  Colorectal cancer in inflammatory bowel disease.

Authors:  Jonathan Potack; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2008-09-30       Impact factor: 4.519

Review 9.  Has the risk of colorectal cancer in inflammatory bowel disease decreased?

Authors:  Nynne Nyboe Andersen; Tine Jess
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease.

Authors:  Elchanan Nussinson; Fahmi Shibli; Azmi Shahbari; Wasseem Rock; Mazen Elias; Irit Elmalah
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.